Starch-mediated colloidal chemistry for highly reversible zinc-based polyiodide redox flow batteries

Aqueous Zn-I flow batteries utilizing low-cost porous membranes are promising candidates for high-power-density large-scale energy storage. However, capacity loss and low Coulombic efficiency resulting from polyiodide cross-over hinder the grid-level battery performance. Here, we develop colloidal chemistry for iodine-starch catholytes, endowing enlarged-sized active materials by strong chemisorption-induced colloidal aggregation. The size-sieving effect effectively suppresses polyiodide cross-over, enabling the utilization of porous membranes with high ionic conductivity. The developed flow battery achieves a high-power density of 42 mW cm−2 at 37.5 mA cm−2 with a Coulombic efficiency of over 98% and prolonged cycling for 200 cycles at 32.4 Ah L−1posolyte (50% state of charge), even at 50 °C. Furthermore, the scaled-up flow battery module integrating with photovoltaic packs demonstrates practical renewable energy storage capabilities. Cost analysis reveals a 14.3 times reduction in the installed cost due to the applicability of cheap porous membranes, indicating its potential competitiveness for grid energy storage.


Statistics
For all statistical analyses, confirm that the following items are present in in the figure legend, table legend, main text, or or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of of all covariates tested
A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g.means) or or other basic estimates (e.g.regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g.Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or or software that are central to to the research but not yet described in in published literature, software must be be made available to to editors and reviewers.We We strongly encourage code deposition in in a community repository (e.g.GitHub).See the Nature Portfolio guidelines for submitting code & software for further information.

Data Policy information about availability of of data
All manuscripts must include a data availability statement This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or or web links for publicly available datasets -A description of of any restrictions on on data availability -For clinical datasets or or third party data, please ensure that the statement adheres to to our policy ZHI Chunyi Apr 5, 5, 2024 Structural characterizations were conducted on on FEI Quanta 450, Bruker Innova AFM, TG/DTA 6300, Bruker D2 D2 Phaser, PerkinElmer Spectrum II; Electrochemical characterizations were conducted on on CHl760E electrochemical workstation, LAND CT2001A battery testing system.
PowerPoint, Origin, Gaussian 09W software package, ORCA software The data that support the findings of of this study are available within the text including the Methods, and Supplemental information.Raw datasets related to to the current work are available from the corresponding author on on reasonable request.

Field-specific reporting
Please select the one below that is the best fit for your research.If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Blinding
Behavioural & social sciences study design All studies must disclose on these points even when the disclosure is negative.

Research sample
Sampling strategy

Timing
The findings apply to all sex and gender.No sex and gender were considered in study design.

Not applicable
Not applicable

City University of Hong Kong
Describe how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Describe any data exclusions.If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Describe the measures taken to verify the reproducibility of the experimental findings.If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.
Describe how samples/organisms/participants were allocated into experimental groups.If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.If blinding was not possible, describe why OR explain why blinding was not relevant to your study.
Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g.qualitative cross-sectional, quantitative experimental, mixed-methods case study).
State the research sample (e.g.Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g.age, sex) and indicate whether the sample is representative.Provide a rationale for the study sample chosen.For studies involving existing datasets, please describe the dataset and source.
Describe the sampling procedure (e.g.random, snowball, stratified, convenience).Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g.pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Indicate the start and stop dates of data collection.If there is a gap between collection periods, state the dates for each sample cohort.
nature portfolio | reporting summary Catholyte and anolyte were prepared with 2 M ZnI2 +1 M starch and 2 M ZnCl2 in deionized water, respectively.The Zn-I flow cells assembly configuration: briefly, PTFE frames served as the flow channel to fix the position of the pretreated three-dimensional electrodes with a geometric area of 4.0 cm2 (2 × 2 cm2) or 25 cm2 (5 × 5 cm2) and thickness of 2.0 mm.Carbon felt (CF) was utilized as both the positive and negative electrode.To make a flow-mode cell, a peristaltic pump was employed to power the circulation of the electrolyte flow through the electrodes.
All attempts to repeat the experiments are successful.

Not applicable
Describe the study conditions for field work, providing relevant parameters (e.g.temperature, rainfall).
State the location of the sampling or experiment, providing relevant parameters (e.g.latitude and longitude, elevation, water depth).
Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Describe any disturbance caused by the study and how it was minimized.
State the source of each cell line used and the sex of all primary cell lines and cells derived from human participants or vertebrate models.
Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.
Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).Permits should encompass collection and, where applicable, export.
Indicate where the specimens have been deposited to permit free access by other researchers.
If new dates are provided, describe how they were obtained (e.g.collection, storage, sample pretreatment and measurement), where they were obtained (i.e.lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.
Provide details on animals observed in or captured in the field; report species and age where possible.Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.
Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex.Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall numbers in this Reporting Summary.Please state if this information has not been collected.Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.

nature portfolio | reporting summary
March 2021 Field-collected samples

Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data Policy information about clinical studies
All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completedCONSORT checklist must be included with all submissions.

Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g.BED files) for the called peaks.

Data access links
May remain private before publication.

Files in database submission
For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Note where the full trial protocol can be accessed OR if not available, explain why.
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.
For "Initial submission" or "Revised version" documents, provide reviewer access links.For your "Final submission" document, provide a link to the deposited data.
Provide a list of all files available in the database submission.The axis labels state the marker and fluorochrome used (e.g.CD4-FITC).
The axis scales are clearly visible.Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Cell population abundance
Gating strategy Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging Experimental design
Design type

Behavioral performance measures
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review.Write "no longer applicable" for "Final submission" documents.
Describe the experimental replicates, specifying number, type and replicate agreement.
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.
Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Describe the software used to collect and analyze the ChIP-seq data.For custom code that has been deposited into a community repository, provide accession details.
Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Identify the instrument used for data collection, specifying make and model number.
Describe the software used to collect and analyze the flow cytometry data.For custom code that has been deposited into a community repository, provide accession details.
Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.
Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.
Indicate task or resting state; event-related or block design.
Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
State number and/or type of variables recorded (e.g.correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g.mean, range, and/or standard deviation across subjects).
nature portfolio | reporting summary Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g.fixed, random or mixed effects; drift or auto-correlation).
Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Describe the type of correction and how it is obtained for multiple comparisons (e.g.FWE, FDR, permutation or Monte Carlo).
Report the measures of dependence used and the model details (e.g.Pearson correlation, partial correlation, mutual information).
Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject-or group-level, and the global and/or node summaries used (e.g.clustering coefficient, efficiency, etc.).
Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.
dual use research of concern Hazards Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to: involve any of these experiments of concern: No Yes Demonstrate how to render a vaccine ineffective Confer resistance to therapeutically useful antibiotics or antiviral agents Enhance the virulence of a pathogen or render a nonpathogen virulent Increase transmissibility of a pathogen Alter the host range of a pathogen Enable evasion of diagnostic/detection modalities Enable the weaponization of a biological agent or toxin Any other potentially harmful combination of experiments and agents We require information from authors about some types of materials, experimental systems and methods used in many studies.Here, indicate whether each material, system or method listed is relevant to your study.If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.
Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type(EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g.original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).
Model type and settings Effect(s) tested Specify type of of analysis: Whole brain ROI-based Both Statistic type for inference (See Eklund et et al. 2016) Correction Models & analysis n/a Involved in in the study Functional and/or effective connectivity